Visual acuity and contrast sensitivity comparison between Tecnis and AcrySof SA60AT intraocular lenses: A multicenter randomized study
Accepted 26 August 2004.
Refers to erratum:
Errata
Journal of Cataract & Refractive Surgery
October 2005 (Vol. 31, Issue 10, Page 1857) Full Text |
Full-Text PDF (37 KB)
Purpose
To evaluate best corrected visual acuity (BCVA) and photopic and mesopic contrast sensitivity in pseudophakic patients implanted either with the aspheric intraocular lens (IOL) designed to correct for corneal spherical aberration or with a conventional IOL.
Setting
Three surgical centers participated this prospective randomized masked comparative study.
Methods
Thirty eyes of 30 patients after aspheric lens implantation (Pfizer/Pharmacia Tecnis Z9000) were compared with 30 eyes of 30 age-matched patients after conventional lens implantation (Alcon AcrySof SA60AT). Two to three months after surgery, best spectacle corrected distance visual acuity was measured using the Early Treatment Diabetic Retinopathy Study chart. Contrast sensitivity was measured by sinusoidal grating charts for distance at photopic (85 cd/m2) and mesopic (6 cd/m2) luminance level with optical correction in place. Tested spatial frequencies were 1.5, 3, 6, 12, and 18 cycles per degree (cpd).
Results
The mean BCVA was −0.053 ± 0.044 logMAR in eyes with the aspheric Tecnis IOL and 0.006 ± 0.059 logMAR in eyes with the conventional AcrySof IOL (P=.0001). Eyes with the aspheric IOL showed better contrast sensitivity at spatial frequencies of 3 cpd (P<.05) and 6, 12, and 18 cpd (P<.01) in photopic and in mesopic conditions. Peak improvement occurred at 18 cpd and was 36% (0.29 log units) in photopic and 54% (0.27 log units) in mesopic conditions.
Conclusions
The aspheric Tecnis IOL yielded better BCVA and better distance contrast sensitivity than the conventional IOL. The differences were clinically significant for higher spatial frequencies. The results give some suggestions for further studies.
From the Ophthalmic Unit, Hospital and University of Verona (Bellucci, Morselli, Chierego), Verona, the Ophthalmic Hospital of Milan (Scialdone, Criscuoli, Moretti), and CAMO (Buratto), Milan, Italy; Pharmacia Corporation (Piers), Groningen, The Nederlands
Supported by a grant from Pharmacia/Pfizer Corp., Peapack, New Jersey.
Dr. Piers is an employee of Pfizer Corporation, Groningen, The Nederlands. Dr. Bellucci has been a consultant to Pharmacia/Pfizer Corp., Peapack, New Jersey.
ABSTRACT